15 December 2024NewsAmericasChristopher Sweeney Executive Director Acuitas Therapeutics, Alison Maddeford Director Litigation & Risk Management Thermo Fisher Scientific, Daniel Yarbrough Head of Intellectual Property Element Biosciences, Madhuri Roy Partner Cooley

WATCH: The challenge of protecting patents and innovation - obviousness-type double patenting post In re Cellect

Speakers from Acuitas Therapeutics, Thermo Fisher Scientific, Element Biosciences, and Cooley examine the risks and implications of obviousness-type double patenting and offer guidance for mitigating its impact on innovation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug

WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025

Strategic IP protection for biotech-related GenAI

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

Patent litigator with biotech and medical device background joins Sterlington

Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency

Fenwick establishes new Boston office with trio of IP partners from Cooley

How pharma should prep for the six-bill avalanche from Congress

WATCH: The challenge of protecting patents and innovation - obviousness-type double patenting post In re Cellect

Editor's picks

Editor's picks

More features